Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

SOPHiA GENETICS and AstraZeneca Partner to Expand Global Access to Liquid Biopsy Testing

NextEdge Admin

10 Sep 2024

2 min 16 sec

SOPHiA GENETICS , a cloud-native healthcare technology leader in data-driven medicine, has announced a significant milestone in the global rollout of the liquid biopsy test MSK-ACCESS®, powered by SOPHiA DDM™, following its initial launch in October 2023. In partnership with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will expand the test’s availability to 20 locations worldwide within the next 12 months.

Liquid biopsy testing, which isolates cell-free DNA (cfDNA) from blood plasma to detect circulating tumor DNA (ctDNA), offers a less invasive alternative to traditional solid tumor testing. This method simplifies patient monitoring and speeds up clinical decision-making, especially when traditional biopsies are not feasible. MSK-ACCESS®, originally developed by Memorial Sloan Kettering Cancer Center, is now decentralized through SOPHiA DDM™'s cloud-based platform, combining advanced algorithms with MSK’s expertise in cancer genomics.

The partnership between SOPHiA GENETICS and AstraZeneca aims to demonstrate the benefits of liquid biopsy testing as a complement to solid tissue analysis. Through a real-world evidence study, they will evaluate the operational and clinical advantages of this method in various labs. Already, 14 major healthcare institutions globally, including renowned cancer centers and laboratories, have adopted MSK-ACCESS® powered with SOPHiA DDM™.

This collaboration seeks to address global health disparities, accelerate cancer research, and improve access to data-driven treatment options worldwide. Kristina Rodnikova, Head of Global Oncology Diagnostics at AstraZeneca, emphasized the commitment to expanding liquid biopsy expertise globally.